AbbVie Chooses North Carolina as Site for $1.4 Billion Advanced Manufacturing Facility
AbbVie has unveiled an ambitious new chapter in its long-term growth strategy with the announcement of a $1.4 billion investment to establish a cutting-edge pharmaceutical manufacturing campus in Durham. Spanning approximately 185 acres, the facility is set to become a cornerstone of the company’s U.S. manufacturing network, combining advanced production capabilities, next-generation laboratory infrastructure, and artificial intelligence (AI)-driven technologies to support the development and supply of innovative medicines.
The planned campus, located near the renowned Research Triangle Park, marks AbbVie’s first significant investment in the state of North Carolina. The selection of this region reflects its well-established reputation as a leading hub for life sciences, biotechnology, and pharmaceutical innovation. With a highly skilled workforce, robust academic partnerships, and a supportive business environment, the area offers an ideal foundation for AbbVie’s long-term expansion and operational excellence.
Construction of the new campus is expected to commence later this year, with full completion targeted by the end of 2028. Once operational, the facility will play a critical role in enhancing AbbVie’s capacity to produce therapies across key therapeutic areas, including immunology, neuroscience, and oncology. By integrating state-of-the-art manufacturing processes with digital and AI-enabled systems, the campus aims to optimize efficiency, improve product quality, and accelerate the delivery of medicines to patients worldwide.
At the heart of the development is a focus on small volume parenteral (SVP) manufacturing. These sterile injectable products—typically less than 100 milliliters in volume—include formats such as vials, prefilled syringes, and cartridges used for both injection and infusion therapies. SVPs are essential for delivering many modern biologic and specialty medicines, particularly in areas like cancer treatment and autoimmune disease management. AbbVie’s new campus is expected to serve as its U.S. center of excellence for SVP manufacturing, reinforcing its ability to meet growing global demand for these advanced therapies.
The initial phase of construction will encompass a comprehensive suite of facilities designed to support both production and innovation. This includes SVP drug product manufacturing units, advanced laboratories equipped for analytical and process development work, warehousing and logistics infrastructure, and administrative spaces. Additionally, the campus will feature employee-focused amenities such as wellness centers, reflecting AbbVie’s commitment to fostering a supportive and productive work environment. Importantly, the design also allows for future expansion, ensuring the site can scale alongside the company’s evolving pipeline and technological needs.
Leadership at AbbVie has emphasized the strategic importance of this investment. Chairman and CEO Robert A. Michael described the project as the company’s largest capital investment to date and a significant milestone in expanding its manufacturing footprint into a new U.S. region. He highlighted that the Durham campus will not only strengthen AbbVie’s ability to support future scientific breakthroughs but also establish a long-term partnership with local communities and state authorities.
Beyond its operational impact, the project is expected to deliver substantial economic benefits. Over the next four years, AbbVie plans to hire approximately 734 employees for the campus, spanning a range of roles including engineers, scientists, manufacturing operators, and laboratory technicians. During the construction phase, the project is anticipated to generate more than 2,000 jobs, providing a significant boost to the local economy and reinforcing the region’s position as a leading employment center for life sciences professionals.
The investment also aligns with AbbVie’s broader commitment to strengthening its presence in the United States. The company has pledged to invest approximately $100 billion over the next decade in U.S.-based research and development, as well as capital expenditures including manufacturing infrastructure. This long-term strategy underscores AbbVie’s focus on maintaining a robust domestic supply chain, advancing innovation, and ensuring resilience in the face of evolving global healthcare demands.
State leadership has welcomed the announcement as a major win for North Carolina’s growing life sciences sector. Governor Josh Stein noted that the combination of world-class research institutions, a thriving innovation ecosystem, and a skilled workforce makes the state an attractive destination for leading biopharmaceutical companies. The addition of AbbVie’s campus further enhances the region’s reputation as a premier location for pharmaceutical manufacturing and development.
AbbVie’s presence in the United States is already extensive, with operations spanning all 50 states and Puerto Rico. The company employs approximately 29,000 people nationwide, including more than 6,000 across its existing U.S. manufacturing sites. Over the past year alone, AbbVie has committed more than $2.2 billion to domestic manufacturing investments and announced the creation of over 1,300 jobs across multiple states, including North Carolina, Illinois, Arizona, and Massachusetts.
The Durham campus represents a continuation of this momentum, signaling AbbVie’s confidence in the future of U.S.-based biopharmaceutical manufacturing. By combining advanced technologies, strategic location advantages, and a focus on workforce development, the facility is poised to play a pivotal role in delivering next-generation therapies to patients.
As the global demand for innovative medicines continues to rise, investments like this underscore the importance of building scalable, technologically advanced manufacturing infrastructure. AbbVie’s new campus not only strengthens its own capabilities but also contributes to the broader ecosystem of pharmaceutical innovation in the United States, ensuring that cutting-edge treatments can reach patients efficiently and reliably for years to come.
About AbbVie
AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio.
Source Link:https://news.abbvie.com/
